Signpath Pharma is a development stage biotechnology company founded in 2006.

Its lead compound is 99.2% pure synthesized curcumin (diferuloylmethane).

Traditional use of curcumin has been restricted to topical skin and gastrointestinal conditions because of negligible absorption when given orally. To extend its clinical use Signpath is developing three different intravenous nanoparticle-sized formulations; liposomal, polymeric, and PLGA.

Proof of efficacy of these formulations against human tumor xenografts in mice has been established. Following intravenous injection of each formulation, we observed transport across the blood brain barrier in mice, rats, and localization in the hippocampus, brainstem and the striatum.



Prospectus of Common Stock
Publications and Posters